PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32317005-4 2020 RESULTS: Our study showed a favorable effect on HbA1c concentration and a slightly unfavorable effect on serum creatinine concentration in users of the five DPP-4 inhibitors, a favorable effect on lipid metabolism in sitagliptin, vildagliptin, and alogliptin users, and a favorable effect on hepatic parameters in sitagliptin, alogliptin, and linagliptin users, in comparison of the baseline and exposure periods. Creatinine 111-121 dipeptidyl peptidase 4 Homo sapiens 157-162 33881796-0 2021 Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes. Creatinine 124-134 dipeptidyl peptidase 4 Homo sapiens 8-30 33881796-1 2021 Results of a post-hoc analysis of urinary dipeptidyl peptidase-4 (DPP-4) protein as a predictor of urinary albumin-to-creatinine ratio (UACR) response to linagliptin treatment based on MARLINA-T2D trial data are described. Creatinine 118-128 dipeptidyl peptidase 4 Homo sapiens 42-64 33881796-1 2021 Results of a post-hoc analysis of urinary dipeptidyl peptidase-4 (DPP-4) protein as a predictor of urinary albumin-to-creatinine ratio (UACR) response to linagliptin treatment based on MARLINA-T2D trial data are described. Creatinine 118-128 dipeptidyl peptidase 4 Homo sapiens 66-71 33881796-4 2021 Furthermore, medium urinary DPP-4 protein levels (between 5.5 and 7.5 natural logarithmic (ln) mug/g creatinine) at baseline allowed for prediction of improved UACR in linagliptin-treated individuals. Creatinine 101-111 dipeptidyl peptidase 4 Homo sapiens 28-33 31627406-6 2019 Urinary albumin-to-creatinine ratio (ACR) was significantly reduced in recipients of DPP-4 inhibitors after 24 weeks (29.2 microg/mg creatinine vs. 14.9 microg/mg creatinine, P < 0.001), whereas urinary ACR was not significantly changed by sulfonylureas (39.9 microg/mg creatinine vs. 43.2 microg/mg creatinine, P = 0.641). Creatinine 19-29 dipeptidyl peptidase 4 Homo sapiens 85-90 31627406-6 2019 Urinary albumin-to-creatinine ratio (ACR) was significantly reduced in recipients of DPP-4 inhibitors after 24 weeks (29.2 microg/mg creatinine vs. 14.9 microg/mg creatinine, P < 0.001), whereas urinary ACR was not significantly changed by sulfonylureas (39.9 microg/mg creatinine vs. 43.2 microg/mg creatinine, P = 0.641). Creatinine 133-143 dipeptidyl peptidase 4 Homo sapiens 85-90 31627406-6 2019 Urinary albumin-to-creatinine ratio (ACR) was significantly reduced in recipients of DPP-4 inhibitors after 24 weeks (29.2 microg/mg creatinine vs. 14.9 microg/mg creatinine, P < 0.001), whereas urinary ACR was not significantly changed by sulfonylureas (39.9 microg/mg creatinine vs. 43.2 microg/mg creatinine, P = 0.641). Creatinine 133-143 dipeptidyl peptidase 4 Homo sapiens 85-90 31627406-6 2019 Urinary albumin-to-creatinine ratio (ACR) was significantly reduced in recipients of DPP-4 inhibitors after 24 weeks (29.2 microg/mg creatinine vs. 14.9 microg/mg creatinine, P < 0.001), whereas urinary ACR was not significantly changed by sulfonylureas (39.9 microg/mg creatinine vs. 43.2 microg/mg creatinine, P = 0.641). Creatinine 133-143 dipeptidyl peptidase 4 Homo sapiens 85-90 31627406-6 2019 Urinary albumin-to-creatinine ratio (ACR) was significantly reduced in recipients of DPP-4 inhibitors after 24 weeks (29.2 microg/mg creatinine vs. 14.9 microg/mg creatinine, P < 0.001), whereas urinary ACR was not significantly changed by sulfonylureas (39.9 microg/mg creatinine vs. 43.2 microg/mg creatinine, P = 0.641). Creatinine 133-143 dipeptidyl peptidase 4 Homo sapiens 85-90 31164243-1 2019 Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. Creatinine 119-129 dipeptidyl peptidase 4 Homo sapiens 12-34 31164243-1 2019 Recently, 2 dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and saxagliptin, adjusted dosing specification from creatinine clearance to glomerular filtration rate, more typically reported in routine laboratory tests. Creatinine 119-129 dipeptidyl peptidase 4 Homo sapiens 36-41 30087386-7 2018 Further, post-operative DPP4-activity was negatively correlated with the extent of post-operative organ injury as measured by SAPS II and SOFA scoring, circulating levels of creatinine and lactate, as well as patients" stay on the ICU. Creatinine 174-184 dipeptidyl peptidase 4 Homo sapiens 24-28 30302966-5 2019 Univariate analyses revealed significant correlations of soluble DPP-4 levels with the total cholesterol (r=0.214, P=0.019) and serum creatinine levels (r=-0.315, P<0.001) and the estimated glomerular filtration rate (eGFR; estimated using the modification of diet in renal disease equation) (r=0.303, P=0.001). Creatinine 134-144 dipeptidyl peptidase 4 Homo sapiens 65-70 30302966-6 2019 The associations of soluble DPP-4 levels with serum creatinine and GFR remained significant after adjusting for age, body mass index, and duration of diabetes. Creatinine 52-62 dipeptidyl peptidase 4 Homo sapiens 28-33 30774748-5 2019 Chronic DPP4 inhibition positively affected renal function with a significant reduction in albuminuria and serum creatinine. Creatinine 113-123 dipeptidyl peptidase 4 Homo sapiens 8-12 31089516-8 2017 Results: Serum DPP-4 concentration was positively correlated with lean body mass, total cholesterol level, and creatinine level. Creatinine 111-121 dipeptidyl peptidase 4 Homo sapiens 15-20 30049504-0 2018 Prescription of DPP-4 Inhibitors to Patients With Adult Type 2 Diabetes Mellitus and Creatinine Clearance >50 mL/min: The UK Primary Care Experience. Creatinine 85-95 dipeptidyl peptidase 4 Homo sapiens 16-21 30049504-2 2018 Adopting a cross-sectional study design and using data from the UK General Practice, this study showed that at least 10% of patients with T2DM and a creatinine clearance level >50 mL/min initiating treatment with a DPP-4 inhibitor were prescribed a dose lower than specified in the Summary of Product Characteristics. Creatinine 149-159 dipeptidyl peptidase 4 Homo sapiens 218-223 29146035-2 2018 The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular filtration rates (eGFRs) from observational studies and clinical trials, and renal events (including kidney failure requiring renal replacement therapy) in recent large prospective cardiovascular outcome trials. Creatinine 186-196 dipeptidyl peptidase 4 Homo sapiens 159-164 26821795-5 2016 RESULTS: Participants in the highest quartile of DPP4 activity had higher HbA1c, homeostatic model assessment of insulin resistance, nitrotyrosine, 8-iso-PGF2a, interleukin-6, high-sensitivity C-reactive protein, mannose 6-phosphate receptor, urinary albumin-to-creatinine ratio and lower estimated glomerular filtration rate compared with participants in the lowest quartile (all p < 0.001). Creatinine 262-272 dipeptidyl peptidase 4 Homo sapiens 49-53 27321309-5 2016 RESULTS: Multiple regression analysis adjusted for age, duration of T2DM, body mass index, serum creatinine, and HbA1c showed that serum DPP-4 levels were positively associated with visceral fat area (beta=0.25, p=0.04), but not subcutaneous fat area (beta=-0.18, p=0.13). Creatinine 97-107 dipeptidyl peptidase 4 Homo sapiens 137-142 27402391-2 2016 The recommended dose of the dipeptidyl peptidase-4 inhibitor saxagliptin is 2.5 mg in patients with moderate or severe renal impairment (creatinine clearance <=50 mL/min). Creatinine 137-147 dipeptidyl peptidase 4 Homo sapiens 28-50 26821795-6 2016 DPP4 activities were associated positively with HbA1c, homeostatic model assessment of insulin resistance, nitrotyrosine, 8-iso-PGF2a, interleukin-6, high-sensitivity C-reactive protein, mannose 6-phosphate receptor, urinary albumin-to-creatinine ratio and negatively with estimated glomerular filtration rate (all p < 0.001). Creatinine 236-246 dipeptidyl peptidase 4 Homo sapiens 0-4 24684351-2 2014 Four of the five commercially available DPP-4 inhibitors are subject to significant renal clearance, and pharmacokinetic studies in people with renal impairment have led to lower recommended doses based on creatinine clearance in order to prevent drug accumulation. Creatinine 206-216 dipeptidyl peptidase 4 Homo sapiens 40-45 22718884-7 2012 DPP4 inhibition resulted in a significant dose-dependent decrease in serum creatinine (1.31 +- 0.32 and 0.70 +- 0.19 mg/dl for VG1 and VG10, respectively, vs. 1.91 +- 0.28 mg/dl for controls at 12 h; P < 0.01). Creatinine 75-85 dipeptidyl peptidase 4 Homo sapiens 0-4 18007554-9 2007 The urinary DPPIV activity was similar in patients (1.52 +/- 0.94 U/mmol creatinine) and controls (1.37 +/- 0.68 U/mmol creatinine) (p = 0.861). Creatinine 73-83 dipeptidyl peptidase 4 Homo sapiens 12-17 25294850-7 2015 At baseline, individuals in the highest quartile of DPP4 activity had higher age, body mass index, waist/hip ratio, systolic blood pressure, diastolic blood pressure, fasting insulin, low-density lipoprotein-cholesterol, interleukin-6, high-sensitivity C-reactive protein, urinary albumin-to-creatinine ratio and lower high-density lipoprotein-cholesterol compared with individuals in the lowest quartile. Creatinine 292-302 dipeptidyl peptidase 4 Homo sapiens 52-56